Business Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Summary of segmental information
Revenues	$ 931,627	$ 795,862	$ 2,341,896	$ 2,009,987
Income (Loss) from Operations	(760,216)	2,203,463	(3,182,883)	(1,452,173)
Amortization and Depreciation Expense	64,032	59,597	172,785	165,042
Interest Income, Net	1,250	1,411	5,284	5,319
Stock-Based Compensation	147,772	141,153	382,774	529,788
Identifiable Assets	5,073,060		5,073,060		8,223,658
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues	862,919	581,943	2,170,761	1,453,558
Income (Loss) from Operations	19,190	5,869	(111,319)	5,921
Amortization and Depreciation Expense	31,357	11,247	84,308	31,119
Interest Income, Net
Stock-Based Compensation	29,103	16,998	33,363	53,830
Identifiable Assets	556,020		556,020		689,266
BioTherapeutics [Member]
Summary of segmental information
Revenues	68,708	5,213,919	171,135	5,556,129
Income (Loss) from Operations	(155,713)	2,684,937	(1,363,572)	(359,792)
Amortization and Depreciation Expense	32,180	47,791	86,913	132,282
Interest Income, Net
Stock-Based Compensation	(49,275)	60,487	63,339	346,995
Identifiable Assets	595,220		595,220		753,767
Corporate [Member]
Summary of segmental information
Revenues
Income (Loss) from Operations	(623,693)	(487,343)	(1,707,992)	(1,098,302)
Amortization and Depreciation Expense	495	559	1,564	1,641
Interest Income, Net
Stock-Based Compensation	167,944	63,668	286,072	128,963
Identifiable Assets	$ 3,921,820		$ 3,921,820		$ 6,780,625